Corcept Therapeutics (NASDAQ:CORT – Get Free Report) released its quarterly earnings data on Wednesday. Here are the key takeaways from Corcept Therapeutics’ conference call:Get Corcept Therapeutics alerts:Second-quarter revenue rose 32% to $256.1 million , while net income increased to $43 million. Corcept Therapeutics Stock Down 1.3%CORT traded down $1.24 during trading on Wednesday, hitting $92.95. Finally, UBS Group set a $135.00 target price on Corcept Therapeutics in a research note on Thursday, May 28th. Further ReadingReceive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.